WANKA ONLINE (01762) announces that it is expected to achieve an annual profit of approximately 60 to 68 million yuan, with a year-on-year increase of approximately 690.3% - 795.7%.
Wan Ka Yi Lian (01762) announced that, based on the preliminary review of the unaudited comprehensive management accounts of the Group for the year ending December 31, 2025, the Group is expected to record during the reporting period: (i) revenue of approximately RMB 4-4.4 billion, an increase of approximately 52.2%-67.5% compared to the same period in 2024; and (ii) net profit of approximately RMB 60-68 million, an increase of approximately 690.3%-795.7% compared to the net profit of RMB 7.592 million in the same period in 2024.
WANKA ONLINE (01762) announced that, based on the preliminary review of the unaudited consolidated management accounts of the Group for the year ended December 31, 2025, the Group expects to record: (i) revenue of approximately RMB 4-4.4 billion, a growth of about 52.2%-67.5% compared to the same period in 2024; and (ii) profit of approximately RMB 60-68 million, an increase of about 690.3%-795.7% compared to the profit of RMB 7.592 million in the same period of 2024.
During the reporting period, the Group's revenue significantly increased, mainly driven by (a) the precise placement of the Group's self-developed AI commercialization service platform, which increased the return on investment (ROI) and encouraged advertisers to reinvest, leading to a steady increase in mobile advertising service revenue; (b) the continuous breakthrough of the Group's overseas business, which significantly increased related revenue, with the Group's overseas revenue reaching approximately RMB 170-210 million, an increase of about 425.5%-549.1% compared to the overseas revenue of RMB 32.351 million in the same period of 2024; and (c) the increase in revenue from non-mobile game distribution.
The Group's net profit during the reporting period also saw synchronous growth, mainly due to (a) the continuous expansion of revenue scale; (b) the effective application of AI technology strategically reducing the Group's operating costs by automatically completing processes such as user analysis, placement optimization, and performance monitoring, driving a continuous growth in net profit.
Related Articles

Chengdu Kanghong Pharmaceutical Group (002773.SZ): KHN707 tablets approved for clinical trials for insomnia.

Northbound funds | Northbound trading saw a net sell of 4.057 billion yuan. Northbound investors once again aggressively bought tech stocks, selling Hong Kong-listed ETFs like TRACKER FUND OF HONG KONG (02800).

On February 25, SHOUGANG CENT (00103) spent 49,400 Hong Kong dollars to repurchase 17,000 shares.
Chengdu Kanghong Pharmaceutical Group (002773.SZ): KHN707 tablets approved for clinical trials for insomnia.

Northbound funds | Northbound trading saw a net sell of 4.057 billion yuan. Northbound investors once again aggressively bought tech stocks, selling Hong Kong-listed ETFs like TRACKER FUND OF HONG KONG (02800).

On February 25, SHOUGANG CENT (00103) spent 49,400 Hong Kong dollars to repurchase 17,000 shares.

RECOMMEND

Robot Concept Hong Kong Stocks Retreat After Spring Gala Rally As 2026 Emerges As Pivotal Year For Mass Production And Commercialization
25/02/2026

Hong Kong IPO Fundraising Surges Tenfold At Start Of Year As 110 A‑Share Companies Queue For Listings
25/02/2026

AI Iteration Risks Surface As Hong Kong Market Diverges; Low‑Valuation, High‑Dividend Legacy Stocks Attract Capital As Safe Havens
25/02/2026


